Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 18;70(19):5819-5828.
doi: 10.1021/acs.jafc.2c00170. Epub 2022 May 9.

Novel Regioselective Synthesis of Urolithin Glucuronides─Human Gut Microbiota Cometabolites of Ellagitannins and Ellagic Acid

Jose M Villalgordo  1 , Laura Trulli  1 , Rocío García-Villalba  2 , Victor García  2 , Yusuf Althobaiti  3 , Francisco A Tomás-Barberán  3   2
Affiliations

Novel Regioselective Synthesis of Urolithin Glucuronides─Human Gut Microbiota Cometabolites of Ellagitannins and Ellagic Acid

Jose M Villalgordo et al. J Agric Food Chem. .

Abstract

Urolithins (dibenzo-pyran-[b,d]-6 one derivatives) are human gut microbiota metabolites produced from the natural food antioxidant ellagic acid. Urolithins are better absorbed than ellagic acid and demonstrate biological activities that suggest that they are responsible for the health effects observed after consuming ellagitannin- and ellagic acid-containing foods. Urolithins occur in the systemic circulation as glucuronide conjugates following phase II metabolism. These phase II conjugates are essential for testing the urolithin mechanisms of action in human cell line bioassays. Urolithin glucuronides are not commercially available, and their biosynthesis leads to mixtures of regional isomers. This study describes a novel and regioselective synthesis of urolithin A (3,8-dihydroxy urolithin) 3- and 8-glucuronides and isourolithin A (3,9-dihydroxy urolithin) 3- and 9-glucuronides. The metabolites were characterized using 1H and 13C NMR spectroscopy and UV spectrophotometry. The presence of these metabolites in human subjects belonging to different urolithin metabotypes was also investigated.

Keywords: ellagic acid; glucuronides; gut microbiota metabolites; synthesis; urolithins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structures of the urolithin glucuronide metabolites. *(Nomenclature following Kay et al., 2020).
Scheme 1
Scheme 1. Synthesis of Isourolithin A 9-Glucuronide (8)
Scheme 2
Scheme 2. Synthesis of Isourolithin A 3-Glucuronide (12)
Scheme 3
Scheme 3. Synthesis of Urolithin A Intermediate 16
Scheme 4
Scheme 4. Synthesis of Urolithin A 8-Glucuronide (18) and 3-Glucuronide (22)
Reagents and conditions: (i) 6, BF3.Et2O (0.15 equiv), CH2Cl2, rt, 1 h., 76% yield; (ii) KF (2 equiv), K2CO3 (2 equiv), MeOH/H2O, rt, 16 h., 46% yield; (iii) pivaloyl chloride (20 equiv), Py, rt, 16 h; 71% yield; (iv) KF (1.1 equiv), MeOH, rt, 1 h., 75% yield; (v) 6, BF3.Et2O (0.15 equiv), CH2Cl2, rt, 1 h, 99% yield; and (vi) KF (2 equiv), K2CO3 (2 equiv), MeOH/H2O (5:1), rt, 16 h, 46%.
Figure 2
Figure 2
HPLC–DAD chromatogram (305 nm) (A) and UV spectra (B) of the synthesized urolithin glucuronides. Urolithin A 8-glucuronide (18); urolithin A 3-glucuronide (22); isourolithin A 9-glucuronide (8); and isourolithin A 3-glucuronide (12).
Figure 3
Figure 3
HPLC–DAD chromatograms at 305 nm of urine samples from volunteers belonging to urolithin metabotype A (A) and urolithin metabotype B (B). Urolithin A 8-glucuronide (18); urolithin A 3-glucuronide (22); isourolithin A 3-glucuronide (12); and urolithin B 3-glucuronide (23).
See this image and copyright information in PMC

References

    1. Cerdá B.; Espín J. C.; Parra S.; Martínez P.; Tomás-Barberán F. A. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora in healthy humans. Eur. J. Nutr. 2004, 43, 205–220. 10.1007/s00394-004-0461-7. - DOI - PubMed
    1. Larrosa M.; García-Conesa M. T.; Espín J. C.; Tomás-Barberán F. A. ellagitannins, ellagic acid and vascular health. Mol. Aspects Med. 2010, 31, 513–539. 10.1016/j.mam.2010.09.005. - DOI - PubMed
    1. Espín J. C.; Larrosa M.; García-Conesa M. T.; Tomás-Barberán F. A. Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: The evidence so far. Evidence-Based Complementary Altern. Med. 2013, 2013, 270418 10.1155/2013/270418. - DOI - PMC - PubMed
    1. Tomás-Barberán F. A.; González-Sarrías A.; García-Villalba R.; Nuñez-Sanchez M. A.; Selma M. V.; García-Conesa M. T.; Espin J. C. Urolithins, the rescue of ‘old’ metabolites to understand a ‘new’ concept; Metabotypes as a nexus between phenolic metabolism, microbiota dysbiosis and host health status. Mol. Nutr. Food Res. 2017, 61, 1500901 10.1002/mnfr.201500901. - DOI - PubMed
    1. Al-Harbi S. A.; Abdulrahman A. O.; Zamzami M. A.; Khan M. I. Urolithins: The gut based polyphenol metabolites of ellagitannins in cancer prevention. A review. Front. Nutr. 2021, 8, 647582 10.3389/fnut.2021.647582. - DOI - PMC - PubMed